An Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Vemurafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 03 Oct 2016 Planned End Date changed from 1 May 2018 to 1 Feb 2019.
- 03 Oct 2016 Planned primary completion date changed from 1 May 2018 to 1 Feb 2019.